Corvus Pharmaceuticals

Apr 30, 2020

•

Mar 31, 2020

Corvus Pharmaceuticals Q1 2020 Earnings Report

Corvus Pharmaceuticals reported financial results for the first quarter ended March 31, 2020.

Key Takeaways

Corvus Pharmaceuticals reported a net loss of $12.9 million for the first quarter ended March 31, 2020, and had cash, cash equivalents and marketable securities totaling $68.7 million at March 31, 2020.

Continued enrolling patients across three clinical stage programs.

Reported positive data updates for ciforadenant, the Adenosine Gene Signature, and CPI-818.

Adapted and updated study protocols to ensure patient and healthcare provider safety in light of the COVID-19 pandemic.

Revised financial forecast for 2020, expecting net cash used in operating activities to be between $29 million and $31 million.